DK2604693T3 - Enkeltkædede TNFSF-molekyler - Google Patents
Enkeltkædede TNFSF-molekyler Download PDFInfo
- Publication number
- DK2604693T3 DK2604693T3 DK13152482.9T DK13152482T DK2604693T3 DK 2604693 T3 DK2604693 T3 DK 2604693T3 DK 13152482 T DK13152482 T DK 13152482T DK 2604693 T3 DK2604693 T3 DK 2604693T3
- Authority
- DK
- Denmark
- Prior art keywords
- leu
- ser
- gly
- ala
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Claims (12)
1. Enkeltkædet fusionspolypeptid, som omfatter: (i) et første opløseligt domæne fra et cytokin i TNF-familien, (ii) en første peptidli nker, (iii) et andet opløseligt domæne fra et cytokin i TNF-familien, (iv) en anden peptidlinker og (v) et tredje opløseligt domæne fra et cytokin i TNF-familien, hvor fusionspolypeptidet er i alt væsentligt ikke-aggregerende, og hvor domænerne (i), (iii) og (v) fra et cytokin i TNF-familien er opløselige humane LIGHT-domæner, som omfatter en aminosyresekvens, der begynder fra aminosyre 93, 94 eller 95 ifølge SEQ ID NO: 16.
2. Polypeptid ifølge krav 1, hvor det opløselige humane LIGHT-domæne omfatter aminosyrerne 93-240, 94-240 eller 95-240 ifølge SEQ ID NO: 16.
3. Polypeptid ifølge krav 1 eller 2, hvor de opløselige domæner omfatter mutationer, som ændrer de opløselige domæners bindingsegenskaber.
4. Polypeptid ifølge et hvilket som helst af kravene 1-3, hvor det andet og det tredje opløselige LIGFIT-domæne (iii) og (v) begynder mellem aminosyre Pro94 og Ala95 ifølge SEQ ID NO: 16.
5. Polypeptid ifølge et hvilket som helst af kravene 1 -4, hvor den første og den anden peptidlinker uafhængigt har en længde på fra 3 til 8 aminosyrer, navnlig en længde på 3, 4, 5, 6, 7 eller 8 aminosyrer, og fortrinsvis er glycin-/serinlinkere, eventuelt omfattende en asparaginrest, som kan være glycosyleret.
6. Polypeptid ifølge et hvilket som helst af kravene 1 -5, som endvidere omfatter et N-terminalt signalpeptiddomæne, som kan omfatte et proteasespaltningssted, og/eller som endvidere omfatter et C-terminalt element, som kan omfatte og/eller være forbundet til et genkendelses-/oprensningsdomæne.
7. Polypeptid ifølge et hvilket som helst af kravene 1 -6, som endvidere omfatter et yderligere domæne N-terminalt og/eller C-terminalt, f.eks. et enkeltkædet antistof eller antistoffragment, såsom et Fab- eller Fc-fragmentdomæne.
8. Nukleinsyremolekyle, som koder for et fusionspolypeptid ifølge et hvilket som helst af kravene 1-7, fortrinsvis operativt forbundet til en ekspressionskontrolsekvens.
9. Isoleret celle eller ikke-human organisme, som er transformeret eller transfi-ceret med et nukleinsyremolekyle ifølge krav 8, hvor cellen f.eks. er en prokaryot celle eller en eukaryot celle, fortrinsvis en pattedyrcelle eller, mere fortrinsvis, en human celle.
10. Farmaceutisk sammensætning, der som aktivt stof omfatter et fusionsprotein ifølge et hvilket som helst af kravene 1-7 eller et nukleinsyremolekyle ifølge krav 8.
11. Farmaceutisk sammensætning ifølge krav 10 til anvendelse til behandling.
12. Diagnostisk sammensætning, der som aktivt stof omfatter et fusionsprotein ifølge et hvilket som helst af kravene 1-7 eller et nukleinsyremolekyle ifølge krav 8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08013112 | 2008-07-21 | ||
EP09780803.4A EP2310509B1 (en) | 2008-07-21 | 2009-07-18 | Tnfsf single chain molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2604693T3 true DK2604693T3 (da) | 2016-05-30 |
Family
ID=41165705
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09780803.4T DK2310509T3 (da) | 2008-07-21 | 2009-07-18 | Enkeltkædede TNFSF-molekyler |
DK13152482.9T DK2604693T3 (da) | 2008-07-21 | 2009-07-18 | Enkeltkædede TNFSF-molekyler |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09780803.4T DK2310509T3 (da) | 2008-07-21 | 2009-07-18 | Enkeltkædede TNFSF-molekyler |
Country Status (14)
Country | Link |
---|---|
US (10) | US8450460B2 (da) |
EP (4) | EP3103875A1 (da) |
JP (5) | JP5674155B2 (da) |
CA (3) | CA2910512C (da) |
CY (1) | CY1116288T1 (da) |
DK (2) | DK2310509T3 (da) |
ES (2) | ES2538122T3 (da) |
HR (1) | HRP20150425T1 (da) |
HU (1) | HUE025236T2 (da) |
PL (2) | PL2604693T3 (da) |
PT (1) | PT2310509E (da) |
SI (1) | SI2310509T1 (da) |
SM (1) | SMT201500135B (da) |
WO (1) | WO2010010051A1 (da) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE047164T2 (hu) * | 2007-11-01 | 2020-04-28 | Univ Arkansas | Kompozíciók és eljárások eimeria elleni immunválasz fokozására |
SI2310509T1 (sl) | 2008-07-21 | 2015-07-31 | Apogenix Gmbh | TNFSF enoverižne molekule |
US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
JP6047142B2 (ja) * | 2011-04-01 | 2016-12-21 | ウニヴェルズィテート シュトゥットガルト | 抗体結合ドメインを有する組換えtnfリガンドファミリーメンバーポリペプチドおよびそれらの使用 |
EP2752429B1 (en) * | 2011-09-16 | 2017-03-01 | Beijing Sunbio Biotech Co. Ltd. | Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof |
NZ626945A (en) * | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
US9127081B2 (en) * | 2012-05-10 | 2015-09-08 | Washington University | Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same |
EP2861616A1 (en) * | 2012-06-13 | 2015-04-22 | Scil Proteins GmbH | Human fusion proteins comprising single chain tnfalpha and targeting domains |
KR102565827B1 (ko) * | 2013-01-09 | 2023-08-11 | 유니버시티 오브 마이애미 | TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법 |
BR112016001114B1 (pt) | 2013-07-19 | 2023-02-14 | Vib Vzw | Composição compreendendo uma proteína de fusão e uso da referida composição |
CN104418952B (zh) * | 2013-09-04 | 2017-08-08 | 上海张江生物技术有限公司 | 一种用于治疗乳腺癌的抗ErbB2双特异性抗体 |
WO2015061206A2 (en) | 2013-10-21 | 2015-04-30 | North Carolina State University | Methods and constructs for compound delivery |
NO2776305T3 (da) | 2014-04-23 | 2018-01-27 | ||
MY191428A (en) * | 2014-11-14 | 2022-06-27 | Hoffmann La Roche | Antigen binding molecules comprising a tnf family ligand trimer |
WO2016112983A1 (en) | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
WO2016124702A1 (en) | 2015-02-06 | 2016-08-11 | Scil Proteins Gmbh | Novel egfr binding proteins |
US10428149B2 (en) | 2015-03-18 | 2019-10-01 | Universitat Stuttgart | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof |
CN114751989A (zh) | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
RU2745801C2 (ru) | 2015-05-04 | 2021-04-01 | Аподжиникс Аг | Одноцепочечные белки-агонисты рецептора cd40 |
PL3322721T3 (pl) | 2015-07-16 | 2022-06-06 | Navigo Proteins Gmbh | Nowe białka wiążące immunoglobulinę i ich zastosowanie w oczyszczaniu na bazie powinowactwa |
WO2017013136A1 (en) | 2015-07-20 | 2017-01-26 | Scil Proteins Gmbh | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
WO2017068181A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain ox40-receptor agonist proteins |
JP6959229B2 (ja) | 2015-10-23 | 2021-11-02 | アポジェニックス アーゲー | 一本鎖gitr受容体アゴニストタンパク質 |
CA3002588C (en) | 2015-10-23 | 2021-11-23 | Apogenix Ag | Single-chain cd137-receptor agonist proteins |
CA3002587A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
JP6917368B2 (ja) * | 2015-10-23 | 2021-08-11 | アポジェニックス アーゲー | 一本鎖cd27受容体アゴニストタンパク質 |
CA3003511A1 (en) | 2015-10-28 | 2017-05-04 | Apogenix Ag | Single-chain tl1a receptor agonist proteins |
WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
WO2017161173A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
EP3452097A1 (en) | 2016-05-04 | 2019-03-13 | Navigo Proteins GmbH | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
CN109153729A (zh) * | 2016-05-13 | 2019-01-04 | 免疫医疗有限责任公司 | Cd40l-fc融合多肽及其使用方法 |
EP3243832A1 (en) * | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
KR102578256B1 (ko) | 2016-08-11 | 2023-09-15 | 리플리겐 코포레이션 | 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질 |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
TWI829628B (zh) | 2016-12-19 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 與靶向4-1bb (cd137)促效劑併用之組合療法 |
BR112019007267A2 (pt) | 2016-12-20 | 2019-07-09 | Hoffmann La Roche | anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes |
EP3565586A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
KR20190104048A (ko) | 2017-01-06 | 2019-09-05 | 이오반스 바이오테라퓨틱스, 인크. | 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물 |
JP7260477B2 (ja) | 2017-02-27 | 2023-04-18 | シャタック ラボ,インコーポレイテッド | Tigit及びlightベースのキメラタンパク質 |
KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
KR102346336B1 (ko) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
US11142558B2 (en) * | 2017-04-06 | 2021-10-12 | Universität Stuttgart | Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
CA3102086A1 (en) | 2017-06-06 | 2018-12-13 | Relinia, Inc. | Single-chain tnf receptor 2 agonist fusion proteins |
WO2019032945A1 (en) * | 2017-08-10 | 2019-02-14 | Oncomed Pharmaceuticals, Inc. | CD40 BINDING AGENT AND USES THEREOF |
US11414466B2 (en) | 2017-11-07 | 2022-08-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer |
BR112020008978A2 (pt) * | 2017-11-09 | 2020-11-10 | Medimmune, Llc | polipeptídeos de fusão biespecíficos e seus métodos de uso |
SG11202004457XA (en) | 2017-11-17 | 2020-06-29 | Iovance Biotherapeutics Inc | Til expansion from fine needle aspirates and small biopsies |
JP2021508104A (ja) | 2017-12-15 | 2021-02-25 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法 |
EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
US20210137930A1 (en) | 2018-02-13 | 2021-05-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
KR20200132913A (ko) | 2018-03-13 | 2020-11-25 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
CN111655731A (zh) | 2018-03-13 | 2020-09-11 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
CA3094957A1 (en) | 2018-03-29 | 2019-10-03 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
BR112020021660A2 (pt) | 2018-04-27 | 2021-02-02 | Iovance Biotherapeutics, Inc. | métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação |
WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
BR112020021648A2 (pt) | 2018-05-14 | 2021-01-26 | Gilead Sciences, Inc. | inibidores de mcl-1 |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
SG11202101787XA (en) | 2018-09-20 | 2021-04-29 | Iovance Biotherapeutics Inc | Expansion of tils from cryopreserved tumor samples |
KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
CR20210213A (es) | 2018-10-30 | 2021-06-24 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de la integrina alfa4beta7 |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US20220033775A1 (en) | 2018-11-05 | 2022-02-03 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathways inhibitors |
BR112021008549A2 (pt) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor |
US20230039976A1 (en) | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
AU2019374761A1 (en) | 2018-11-05 | 2021-06-10 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
EP3898949A1 (en) | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
US20220064245A1 (en) * | 2018-12-21 | 2022-03-03 | Vib Vzw | Fusion proteins comprising a cytokine and scaffold protein |
KR20210136050A (ko) | 2019-03-01 | 2021-11-16 | 이오반스 바이오테라퓨틱스, 인크. | 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도 |
KR20220002336A (ko) | 2019-03-29 | 2022-01-06 | 미스트 쎄라퓨틱스, 엘엘씨 | T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법 |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2021108727A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Inc. | Method of producing tumor-reactive t cell composition using modulatory agents |
EP4073236A1 (en) | 2019-12-11 | 2022-10-19 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
EP4110799A1 (en) | 2020-02-27 | 2023-01-04 | Myst Therapeutics, LLC | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
JP2023524108A (ja) | 2020-05-04 | 2023-06-08 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 改良された腫瘍反応性t細胞の選択 |
EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CN115956086A (zh) * | 2020-05-06 | 2023-04-11 | 萨摩亚商柏沛生医股份有限公司 | 用于针对癌症及传染病的免疫疗法的融合蛋白 |
US20230212260A1 (en) | 2020-05-15 | 2023-07-06 | Apogenix Ag | Multi-specific immune modulators |
MX2023000883A (es) | 2020-07-24 | 2023-02-22 | Genentech Inc | Metodos para la expresion de una fusion anticuerpo-multimero. |
KR20230074799A (ko) | 2020-10-01 | 2023-05-31 | 이뮤니컴 인코포레이티드 | 리간드의 침출 감소 |
JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球療法によるnsclc患者の治療 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
WO2022140797A1 (en) * | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
BR112023018117A2 (pt) | 2021-03-09 | 2023-10-31 | Hoffmann La Roche | Imunoconjugados |
BR112023021665A2 (pt) | 2021-04-19 | 2023-12-19 | Iovance Biotherapeutics Inc | Método para tratar um câncer, e, composição |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
EP4148067A1 (en) | 2021-09-08 | 2023-03-15 | F. Hoffmann-La Roche AG | Method for the expression of an antibody-multimer-fusion |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
CA3235824A1 (en) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
WO2023144393A1 (en) * | 2022-01-28 | 2023-08-03 | Fundació Centre De Regulació Genòmica | Therapeutic cytokines and methods |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
DE69332981T2 (de) * | 1992-10-23 | 2004-05-19 | Immunex Corp., Seattle | Methoden zur herstellung löslicher, oligomerer proteine |
WO2001025277A1 (en) | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
DE10122140A1 (de) * | 2001-05-08 | 2002-11-28 | Apotech Res & Dev Ltd | Rekombinante Fusionsproteine und deren Trimere |
EA007810B1 (ru) * | 2001-11-16 | 2007-02-27 | Фармекса А/С | Иммуногенные миметики мультимерных белков с нерегулярными вставками т-клеточных эпитопов |
JPWO2005056605A1 (ja) * | 2003-12-12 | 2007-12-06 | 中外製薬株式会社 | 3量体以上の受容体を認識する改変抗体 |
DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
EP1894940A1 (en) * | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
CA2860950C (en) | 2007-07-10 | 2017-08-01 | Apogenix Gmbh | Tnf superfamily collectin fusion proteins |
SI2310509T1 (sl) | 2008-07-21 | 2015-07-31 | Apogenix Gmbh | TNFSF enoverižne molekule |
ES2593049T3 (es) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
US10428149B2 (en) | 2015-03-18 | 2019-10-01 | Universitat Stuttgart | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof |
CN109153729A (zh) * | 2016-05-13 | 2019-01-04 | 免疫医疗有限责任公司 | Cd40l-fc融合多肽及其使用方法 |
-
2009
- 2009-07-18 SI SI200931179T patent/SI2310509T1/sl unknown
- 2009-07-18 EP EP16162935.7A patent/EP3103875A1/en active Pending
- 2009-07-18 DK DK09780803.4T patent/DK2310509T3/da active
- 2009-07-18 ES ES09780803.4T patent/ES2538122T3/es active Active
- 2009-07-18 EP EP09780803.4A patent/EP2310509B1/en active Active
- 2009-07-18 PL PL13152482.9T patent/PL2604693T3/pl unknown
- 2009-07-18 CA CA2910512A patent/CA2910512C/en active Active
- 2009-07-18 EP EP13152482.9A patent/EP2604693B1/en active Active
- 2009-07-18 DK DK13152482.9T patent/DK2604693T3/da active
- 2009-07-18 EP EP14175292.3A patent/EP2806029B1/en active Active
- 2009-07-18 CA CA3092223A patent/CA3092223C/en active Active
- 2009-07-18 WO PCT/EP2009/059269 patent/WO2010010051A1/en active Application Filing
- 2009-07-18 CA CA2731388A patent/CA2731388C/en active Active
- 2009-07-18 JP JP2011519138A patent/JP5674155B2/ja active Active
- 2009-07-18 HU HUE09780803A patent/HUE025236T2/en unknown
- 2009-07-18 ES ES13152482T patent/ES2571879T3/es active Active
- 2009-07-18 PT PT97808034T patent/PT2310509E/pt unknown
- 2009-07-18 PL PL09780803T patent/PL2310509T3/pl unknown
- 2009-07-18 US US13/055,109 patent/US8450460B2/en active Active
-
2013
- 2013-05-24 US US13/902,328 patent/US8921519B2/en active Active
-
2014
- 2014-06-30 US US14/320,261 patent/US9359420B2/en active Active
- 2014-09-02 JP JP2014177737A patent/JP6140117B2/ja active Active
- 2014-09-02 JP JP2014177736A patent/JP6046089B2/ja active Active
- 2014-12-02 US US14/558,681 patent/US9340599B2/en active Active
-
2015
- 2015-04-20 HR HRP20150425TT patent/HRP20150425T1/hr unknown
- 2015-04-21 CY CY20151100367T patent/CY1116288T1/el unknown
- 2015-06-12 SM SM201500135T patent/SMT201500135B/xx unknown
-
2016
- 2016-06-03 US US15/172,393 patent/US9725495B2/en active Active
- 2016-09-20 JP JP2016183065A patent/JP2017029158A/ja active Pending
- 2016-12-05 US US15/369,657 patent/US20170081381A1/en not_active Abandoned
-
2017
- 2017-04-27 JP JP2017088979A patent/JP6694409B2/ja active Active
- 2017-07-07 US US15/643,787 patent/US10118953B2/en active Active
-
2018
- 2018-10-10 US US16/156,867 patent/US10640543B2/en active Active
-
2019
- 2019-02-28 US US16/289,361 patent/US10519208B2/en active Active
-
2020
- 2020-03-27 US US16/832,183 patent/US11214605B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11214605B2 (en) | Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells | |
CA2963124C (en) | Tnf superfamily collectin fusion proteins | |
EP2829550A2 (en) | Fusion proteins forming trimers |